ZYME Oct 2024 17.500 call
| Previous close | 0.3500 |
| Open | 0.3500 |
| Bid | 0.2000 |
| Ask | 0.6000 |
| Strike | 17.50 |
| Expiry date | 2024-10-18 |
| Day's range | 0.3500 - 1.1700 |
| Contract range | N/A |
| Volume | |
| Open interest | 45 |
GlobeNewswireZymeworks Announces Participation in Upcoming Investor Conferences
VANCOUVER, British Columbia, May 28, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced that management will participate in the following upcoming investor conferences: Jefferies Global Healthcare Conference: Zymeworks’ management will participate in one-on-one meetings on June 5-6 and a fireside chat
Simply Wall St.Zymeworks Inc. (NASDAQ:ZYME) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
Zymeworks Inc. ( NASDAQ:ZYME ) just released its latest quarterly report and things are not looking great. It was not a...
- GlobeNewswire
Zymeworks Provides Corporate Update and Reports First Quarter 2024 Financial Results
Reported $420.5 million in cash resources as of March 31, 2024, which when combined with certain anticipated regulatory milestone payments provides projected cash runway into 2H 2027Completion of rolling biologics license application (BLA) filing with the U.S. Food and Drug Administration (FDA) for zanidatamab as second-line treatment for biliary tract cancers (BTC) in the United States (U.S.) by our partner, Jazz PharmaceuticalsExpected initiation of a Phase 3 clinical trial for zanidatamab in
